Jean-Louis Escary
No más puestos en curso
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Abdenour Chelouah | M | - |
Université Pierre et Marie Curie
| 6 años |
Jean-Marc Lulin | M | - |
Université Pierre et Marie Curie
| 3 años |
Jean-Marc Giry | M | - |
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | - |
Juliette Laquerrière | F | 54 |
Université Pierre et Marie Curie
| 1 años |
Shu Yi Zhang | M | 60 |
Université Pierre et Marie Curie
| 3 años |
Jacques Dumas | M | 58 |
Université Pierre et Marie Curie
| 4 años |
Yvon E. Cayre | M | - |
Université Pierre et Marie Curie
| - |
Philippe Margaron | M | - |
Université Pierre et Marie Curie
| 3 años |
Cohen Georges | M | - |
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | - |
Philippe Remes | M | - |
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | - |
Véronique Miette | F | 57 |
Université Pierre et Marie Curie
| 4 años |
Eric Peltier | M | 58 |
Université Pierre et Marie Curie
| 1 años |
Jonathan Hanley | M | - |
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | - |
Geneviéve B. Berger | M | 69 |
Université Pierre et Marie Curie
| 9 años |
Frank Mathias | M | 62 |
Université Pierre et Marie Curie
| 3 años |
Jean-Yves Nothias | M | 62 |
Université Pierre et Marie Curie
| 3 años |
Christophe Bureau | M | 57 |
Université Pierre et Marie Curie
| 3 años |
Laurent Sandrin | M | 51 |
Université Pierre et Marie Curie
| 4 años |
Gang Zhou | M | 59 |
Université Pierre et Marie Curie
| 1 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Francia | 19 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Jean-Louis Escary
- Red Personal